rofecoxib has been researched along with Gastroduodenal Ulcer in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicentre, randomised, double blind, 12 week study, patients with rheumatoid arthritis were allocated to rofecoxib 50 mg once daily (n=219), naproxen 500 mg twice daily (n=220), or placebo (n=221)." | 9.10 | Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. ( Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 9.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "In this multicentre, randomised, double blind, 12 week study, patients with rheumatoid arthritis were allocated to rofecoxib 50 mg once daily (n=219), naproxen 500 mg twice daily (n=220), or placebo (n=221)." | 5.10 | Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. ( Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 5.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| " Dosing should be [figure: see text] cautious in old patients, however, because of the ability of NSAIDs and coxibs to cause fluid retention, heart failure, and hypertension." | 2.41 | Gastrointestinal safety of COX-2 specific inhibitors. ( Hawkey, CJ; Jones, JI, 2001) |
| "Celecoxib and rofecoxib have been used in Norway since 2000." | 2.41 | [A critical evaluation of side effect data on COX-2 inhibitors]. ( Pomp, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 39 (90.70) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almansa, C | 1 |
| Alfón, J | 1 |
| de Arriba, AF | 1 |
| Cavalcanti, FL | 1 |
| Escamilla, I | 1 |
| Gómez, LA | 1 |
| Miralles, A | 1 |
| Soliva, R | 1 |
| Bartrolí, J | 1 |
| Carceller, E | 1 |
| Merlos, M | 1 |
| García-Rafanell, J | 1 |
| Schneeweiss, S | 1 |
| Glynn, RJ | 1 |
| Avorn, J | 1 |
| Mamdani, M | 1 |
| Mogun, H | 1 |
| Solomon, DH | 1 |
| Stover, RR | 1 |
| Wiens, BL | 1 |
| Heyse, JF | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Hawkey, CJ | 5 |
| Laine, L | 2 |
| Simon, T | 1 |
| Quan, H | 3 |
| Shingo, S | 1 |
| Evans, J | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Sturkenboom, MC | 1 |
| Burke, TA | 1 |
| Dieleman, JP | 1 |
| Tangelder, MJ | 1 |
| Lee, F | 1 |
| Goldstein, JL | 1 |
| Lamarque, D | 1 |
| Chang, SY | 1 |
| Howden, CW | 1 |
| Hollenz, M | 1 |
| Labenz, J | 1 |
| Dai, C | 1 |
| Stafford, RS | 1 |
| Alexander, GC | 1 |
| McCarthy, DM | 1 |
| Klasser, GD | 1 |
| Epstein, J | 1 |
| Lanas, A | 1 |
| Baron, JA | 1 |
| Sandler, RS | 1 |
| Horgan, K | 1 |
| Bolognese, J | 1 |
| Oxenius, B | 1 |
| Watson, D | 1 |
| Cook, TJ | 1 |
| Schoen, R | 1 |
| Burke, C | 1 |
| Loftus, S | 1 |
| Niv, Y | 1 |
| Ridell, R | 1 |
| Morton, D | 1 |
| Bresalier, R | 1 |
| Takeuchi, K | 1 |
| Tanaka, A | 1 |
| Kato, S | 1 |
| Aihara, E | 1 |
| Amagase, K | 1 |
| Schachna, L | 1 |
| Ryan, PF | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Watson, DJ | 1 |
| Harper, SE | 2 |
| Zhao, PL | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 2 |
| Dionne, R | 1 |
| Blondon, H | 1 |
| Goldkind, L | 1 |
| Bombardier, C | 1 |
| Reicin, A | 1 |
| Shapiro, D | 1 |
| Burgos-Vargas, R | 1 |
| Davis, B | 1 |
| Day, R | 1 |
| Ferraz, MB | 1 |
| Hochberg, MC | 1 |
| Kvien, TK | 1 |
| Schnitzer, TJ | 1 |
| Jackson, L | 1 |
| Mortensen, E | 1 |
| Lines, CR | 1 |
| Brzozowski, T | 1 |
| Konturek, PC | 1 |
| Konturek, SJ | 1 |
| Pajdo, R | 1 |
| Schuppan, D | 1 |
| Drozdowicz, D | 1 |
| Ptak, A | 1 |
| Pawlik, M | 1 |
| Nakamura, T | 1 |
| Hahn, EG | 1 |
| Simon, B | 1 |
| Kellner, H | 1 |
| Lems, WF | 1 |
| van de Laar, MA | 1 |
| Bijlsma, JW | 1 |
| Patrono, C | 1 |
| Patrignani, P | 1 |
| García Rodríguez, LA | 1 |
| Nguyen, A | 1 |
| Chaiton, A | 1 |
| Nakamura, H | 1 |
| Jones, JI | 1 |
| Brinker, AD | 1 |
| Bonnel, RA | 1 |
| Feight, AG | 1 |
| Nourjah, P | 1 |
| Pomp, E | 1 |
| Miyake, K | 1 |
| Sakamoto, C | 1 |
| Shaughnessy, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model[NCT00026819] | Phase 2 | 150 participants | Interventional | 2001-11-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for rofecoxib and Gastroduodenal Ulcer
| Article | Year |
|---|---|
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Gastroint | 2004 |
Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cyclooxygenase Inhibitors; Diclofenac; Gas | 2002 |
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials | 2005 |
COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 1999 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2001 |
[Safety of specific cyclo-oxygenase 2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Humans; Inci | 2001 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pep | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
COX-1 and COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
Arthritis. Should you be taking a COX-2 inhibitor?
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cycloo | 2001 |
Gastrointestinal safety of COX-2 specific inhibitors.
Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygena | 2001 |
[A critical evaluation of side effect data on COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2002 |
5 trials available for rofecoxib and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cycl | 2003 |
Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Europe; | 2007 |
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Endoscopy, Gastrointestinal; | 2001 |
21 other studies available for rofecoxib and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites | 2003 |
NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxy | 2009 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cycloox | 2002 |
Testing for interaction in studies of noninferiority.
Topics: Bias; Computer Simulation; Confidence Intervals; Data Interpretation, Statistical; Humans; Lactones; | 2003 |
Underutilization of preventive strategies in patients receiving NSAIDs.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cohort | 2003 |
[Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Clinical Trials a | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
[Gastrointestinal complications under NSAID treatment in the doctor's office].
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Clinical Trials as Topic; Dicl | 2004 |
National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
Topics: Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Attitude of Health Personnel | 2005 |
Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa.
Topics: Animals; Benzamides; Benzoates; Gastric Mucosa; Indomethacin; Intestinal Mucosa; Lactones; Peptic Ul | 2007 |
New versus old drugs for arthritis.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Huma | 1999 |
COX-2 inhibitors. Magic bullets or merely mortal?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
COX-2 inhibitors: better than ibuprofen for dental pain?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 1999 |
Refecoxib versus placebo ulcer rates.
Topics: Cyclooxygenase Inhibitors; Humans; Intestinal Mucosa; Lactones; Peptic Ulcer; Placebos; Randomized C | 2000 |
Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor.
Topics: Animals; Antibodies; Blotting, Western; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 2000 |
[Prof. Bernd Simon on nonsteroidal anti-inflammatory drugs. Gastrointestinal complications are unpredictable].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Humans; Lactones; Peptic Ulcer; | 2001 |
[Therapy of arthrosis. Life threatening gastrointestinal events can be reduced].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 2001 |
[Results of the VIGOR study. Rofecoxib halves the complication rate].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, Dr | 2001 |
[Selective COX-2 inhibitor. Stomach protection--but not always].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycl | 2001 |
Celecoxib and rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Hemo | 2001 |
Right ballpark, wrong base: assessing safety of NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pep | 2002 |